Rare Disease Target Identification Services
Target identification aims to identify whether genes, proteins, metabolites, and other biomolecules that play important roles in the occurrence and development of diseases can be used as targets for the therapeutics of diseases. Our company provides a one-stop service and complete facilities to assist you in leading the target identification for rare diseases.
Target Identification for Rare Diseases
Target identification is a complex and multi-layered process, built upon a deep understanding of the specificity of each rare disease at the molecular and cellular levels. Utilizing technologies such as genomics, proteomics, and metabolomics, scientists can thoroughly dissect the pathological mechanisms of rare diseases, thereby identifying potential therapeutic targets.
Fig.1 Exploratory techniques for target identification. (Pun, F. W., et al., 2023) Approaches of Target Identification
For target identification for rare diseases, target-based and phenotype-based approaches complement each other, laying the foundation for the development of multiple drug platforms. The vast majority of approved drugs include small molecules, monoclonal antibodies, and biologics. Additionally, many cell therapy and gene therapy approaches are currently in the research phases. This indicates an urgent need for the development of new drugs for rare diseases to help alleviate the conditions of individuals, which also holds significant market prospects.
- Target-based Approach
With the popularization and cost reduction of next-generation sequencing technologies, molecular target-based drug therapy development becomes a mainstream. In this process, gene products closely associated with diseases, including various kinds of protein kinases, ligand-receptor pairs, transcription factors, and ion channels, are first identified and serve as targets for therapeutics.
- Phenotype-based Approach
Phenotype-based approach provides ample avenues for mechanistic studies by identifying the precise protein components that cause phenotypic changes in readily available effective drugs. This process can identify the molecular targets directly affected by drugs and separate them from other indirectly responsive gene products. The continuous innovation of technologies such as mass spectrometry provides a broad platform.
Our Services
Our company has a mature and comprehensive target identification system, providing you with an experienced multi-disciplinary high-level team to support the development of rare disease target identification. We have complete gene sequencing, bioinformatics analysis, and other technologies to further support the target identification of rare diseases. Our rare disease target identification services include but are not limited to:
Target
Identification
-
Have A
Compound -
Phenotype-based
Approach -
Target
Deconvolution
-
Want A
Compound -
Target-based
Approach -
Target
Discovery
Target
Candidate
Target
Validation
In addition, we provide target identification services utilizing the tools from multiple perspectives, including but not limited to:
- Structural Genomics
- Functional Genomics
- Protein Analytical Microarray
- Functional Protein Microarray
- Reverse Phase Protein Microarray
- Bioinformatics
Why Choose Us?
- Fast-cycle comprehensive service
- Professional multidisciplinary experts
- End-to-end project design, assessment, and reporting
- Next-generation biological experimentation devices
- Competitive pricing and fast turnaround time
- Fast and cost-efficient workflow
With the branches set up around the world and the participation of multidisciplinary experts, our company is committed to providing you with high-quality target identification and development services to help you lead drug development for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Pun, F. W., et al., Ozerov, and Alex Zhavoronkov. "AI-powered therapeutic target discovery." Trends in Pharmacological Sciences (2023).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.